Disease-modifying treatments for Alzheimer's disease: A perspective based on experience with R-Flurbiprofen

Alzheimer's and Dementia

Volumn 2, Issue 3, 2006, Pages 150-152

  Wilcock, Gordon K ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CHOLINESTERASE INHIBITOR; DONEPEZIL; FLURBIPROFEN; NEUROPROTECTIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; RIVASTIGMINE;

ALZHEIMER DISEASE; ANEMIA; CLINICAL TRIAL; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG TARGETING; EDITORIAL; EFFECT SIZE; ENANTIOMER; EOSINOPHILIA; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; LOWER RESPIRATORY TRACT INFECTION; MENTAL DISEASE; METHODOLOGY; OUTCOMES RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; RACEMIC MIXTURE; TIME MANAGEMENT; URINE INCONTINENCE;

EID: 33744944280     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2006.03.013     Document Type: Editorial

References (7)

1. Hashimoto M., Kazui H., Matsumoto K., Nakano Y., Yasuda M., and Mori E. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?. Am J Psychiatry 162 4 (2005) 676-682
2. Venneri A., McGeown W.J., and Shanks M.F. Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease. Neuroreport 16 2 (2005) 107-110
3. Francis P.T., Nordberg A., and Arnold S.E. A preclinical view of cholinesterase inhibitors in neuroprotection. Do they provide more than symptomatic benefits in Alzheimer's disease?. Trends Pharmacol Sci 26 2 (2005) 104-111
4. Eriksen J.L., Sagi S.A., Smith T.E., Weggen S., Das P., McLendon D.C., et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 112 3 (2003) 440-449
5. Weggen S., Eriksen J.L., Das P., Sagi S.A., Wang R., Pietrzik C.U., et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414 6860 (2001) 212-216
6. Weggen S., Eriksen J.L., Sagi S.A., Pietrzik C.U., Ozols V., Fauq A., et al. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J Biol Chem 278 34 (2003) 31831-31837
7. Wilcock G.K., Black S., Haworth J., et al. A placebo-controlled, double-blind trial of the selective Ab-42 lowering agent, flurizan (MPC-7869, (R)-flurbiprofen) in patients with mild to moderate Alzheimer's disease. [abstract]. Alzheimer's & Dementia 1 (2005) S95 Abstract O2-01-05